The Priority Review

Tag

KRKA

1 story

  1. Approvals

    CHMP recommends marketing authorization for Ruxolitinib Krka

    On 12 November 2026 the CHMP adopted a positive opinion, recommending the granting of a marketing authorization for Ruxolitinib Krka, intended for the treatment of myelofibrosis, polycythaemia vera and graft-versus-host disease. The generic will be available as 5 mg, 10 mg, 15 mg and 20 mg tablets.